GlassScriptPhysician profile
Rajan Regmi
NPI 1447413570
$968.90
in general payments reported to CMS, 2019-2025
10 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $16.90 · 2024: $207 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Education: $21.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.83 |
| Education | $21.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $323.04 | 2022-2025 | Rayaldee |
| Amgen INC. | $175.00 | 2024-2025 | Tavneos, Aranesp, Parsabiv |
| Novartis Pharmaceuticals Corporation | $129.82 | 2024 | |
| Glaxosmithkline, LLC. | $126.00 | 2025 | Benlysta |
| Radius Health, INC. | $92.86 | 2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $54.09 | 2025 | Yorvipath |
| Daiichi Sankyo INC. | $26.02 | 2022 | |
| Lilly USA, LLC | $16.90 | 2023 | Jardiance |
| Vifor Pharma, INC. | $14.20 | 2025 | Veltassa |
| Travere Therapeutics, INC. | $10.97 | 2024-2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Regmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.